Optimizerx Corporation ( (OPRX) ) has released its Q1 earnings. Here is a breakdown of the information Optimizerx Corporation presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
OptimizeRx Corporation, a healthcare technology company based in Waltham, Massachusetts, specializes in connecting life sciences brands with healthcare professionals and patients through innovative AI-driven tools. The company recently reported its financial results for the first quarter of 2025, showcasing significant growth and strategic advancements.
In the first quarter of 2025, OptimizeRx reported a revenue increase of 11% year-over-year, reaching $21.9 million. Gross profit also rose by 9% to $13.3 million. The company managed to reduce its GAAP net loss to $2.2 million, a notable improvement from the $6.9 million loss in the same period last year. Additionally, OptimizeRx achieved a non-GAAP net income of $1.5 million, marking a positive turnaround from the previous year’s non-GAAP net loss.
Key financial metrics highlighted in the report include an increase in adjusted EBITDA to $1.5 million, up from a negative $0.3 million in the prior year. The company also reported a strong cash position with $16.6 million in cash, cash equivalents, and short-term investments. OptimizeRx’s strategic shift towards subscription-based revenue streams has begun to show results, with over 5% of expected 2025 sales already converted.
Looking ahead, OptimizeRx has raised its full-year 2025 guidance, expecting revenue between $101 million and $106 million and adjusted EBITDA between $13 million and $15 million. The company’s management remains optimistic about its future performance, driven by operational excellence and strengthened partnerships, aiming to achieve Rule of 40 performance in the coming years.